Log in

NASDAQ:ALRNAileron Therapeutics Stock Price, Forecast & News

$1.16
+0.03 (+2.65 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.10
Now: $1.16
$1.18
50-Day Range
$0.67
MA: $1.10
$1.62
52-Week Range
$0.25
Now: $1.16
$1.99
Volume338,500 shs
Average Volume903,871 shs
Market Capitalization$44.29 million
P/E RatioN/A
Dividend YieldN/A
Beta3.72
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.
Read More
Aileron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.95 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.58 per share

Profitability

Net Income$-29,370,000.00

Miscellaneous

Employees23
Market Cap$44.29 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

How has Aileron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ALRN stock has increased by 187.8% and is now trading at $1.16. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aileron Therapeutics.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aileron Therapeutics.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) announced its earnings results on Monday, May, 11th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.04. View Aileron Therapeutics' earnings history.

What price target have analysts set for ALRN?

3 brokers have issued 1 year target prices for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' share price to reach $3.50 in the next year. This suggests a possible upside of 201.7% from the stock's current price. View analysts' price targets for Aileron Therapeutics.

What are Wall Street analysts saying about Aileron Therapeutics stock?

Here are some recent quotes from research analysts about Aileron Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. " (6/2/2020)
  • 2. HC Wainwright analysts commented, "Our $6 price target is based on probability-adjusted forecasts for ALRN-6924 for myelopreservation, and ALRN-6924 in combination with Ibrance in MDM2-amplified solid tumor patients." (9/11/2019)

Has Aileron Therapeutics been receiving favorable news coverage?

News articles about ALRN stock have trended negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aileron Therapeutics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the near term. View the latest news about Aileron Therapeutics.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 606,700 shares, an increase of 6.2% from the May 31st total of 571,200 shares. Based on an average daily volume of 813,800 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.4% of the company's shares are sold short. View Aileron Therapeutics' Current Options Chain.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Amarin (AMRN), Agile Therapeutics (AGRX), Lexicon Pharmaceuticals (LXRX), Opko Health (OPK), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), OpGen (OPGN), Acasti Pharma (ACST) and Advanced Micro Devices (AMD).

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
  • Mr. Richard J. Wanstall, VP of Fin. & Operations
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.16.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $44.29 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.